Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »
Sally Church

Sally Church

Interested in Pharma, Biotech, Science and cancer... Find me at http://www.pharmastrategyblog.com also love food, wine, the NFL and cricket. Hi!
albotas: Watch This Girl Build Her Own Prosthetic Leg Out Of LEGO Pieces It’s awesome watching this girl scavenge for all the right pieces (a feeling I’m sure we’re all familiar with), and become increasingly delighted at her progress. See for yourself. The uploader, AmputeeOT, says: Someone in my research lab jokingly suggested I make a... - http://maverickny.tumblr.com/post...
albotas:
  Watch This Girl Build Her Own Prosthetic Leg Out Of LEGO Pieces 
It’s awesome watching this girl scavenge for all the right pieces (a feeling I’m sure we’re all familiar with), and become  increasingly delighted at her progress. See for yourself.
 
 
The uploader, AmputeeOT, says:
  
Someone in my research lab jokingly suggested I make a prosthetic leg out of legos.
 
Please don’t do this yourself, I don’t want you to fall and get hurt!
 
Sometimes, you just need to be silly.
  
Could you imagine a world where half LEGO cyber amazon warrior women roam the Earth? Sounds like a plot for an action-packed, sexy pulp comic/my dreams come true.
ASH 2012 update on ARRY-520 in multiple myeloma - http://pharmastrategyblog.com/2013...
Will biomarkers revolutionalise treatment with tivozanib? - http://pharmastrategyblog.com/2013...
ASCO GU update on tivozanib in advanced clear cell renal cancer - http://pharmastrategyblog.com/2013...
Tumor Lysis Syndrome – what is it and why is it important in cancer research? - http://pharmastrategyblog.com/2013...
Making a difference in Advanced Prostate Cancer – an interview with Bertrand Tombal - http://pharmastrategyblog.com/2013...
Making a difference in pancreatic cancer – an interview with Dr Hedy Lee Kindler - http://pharmastrategyblog.com/2013...
Will ASCO GI herald a new era for pancreatic cancer? - http://pharmastrategyblog.com/2013...
Effectively targeting KRAS in lung cancer with a MEK inhibitor - http://pharmastrategyblog.com/2012...
Time to rethink cancer clinical trials strategy? - http://pharmastrategyblog.com/2012...
Zaltrap – a simple dosing error or not? - http://pharmastrategyblog.com/2012...
Prospect of Abraxane in Pancreatic Cancer excites ESMO 2012 - http://pharmastrategyblog.com/2012...
Update on bavituximab in non-squamous lung cancer - http://pharmastrategyblog.com/2012...
ASCO 2012 Update 2: Overcoming resistance in metastatic melanoma - http://pharmastrategyblog.com/2012...
A surfeit of riches in CLL and NHL: on bruton kinase and PI3K delta inhibitors - http://pharmastrategyblog.com/2012...
ASCO 2012 Update 1: Advanced Lung Cancer - http://pharmastrategyblog.com/2012...
Interested in the PI3K-AKT-mTOR pathway in cancer research? - http://pharmastrategyblog.com/2012...
Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone - http://pharmastrategyblog.com/2012...
Stunning data with dabrafenib (BRAFV600E) in metastatic melanoma and brain metastases - http://pharmastrategyblog.com/2012...
Reflections of a Medical Oncologist on AACR 2012 - http://pharmastrategyblog.com/2012...
ASCO 2012 Preview – Highlights of key data emerging from Chicago - http://pharmastrategyblog.com/2012...
Ribonucleases (RNase) – clinical applications for cancer therapy - http://pharmastrategyblog.com/2012...
Ribonucleases (RNase) what are they and why are they relevant to cancer? - http://pharmastrategyblog.com/2012...
American Society for Cancer Research Meeting 2012 - http://pharmastrategyblog.com/2012...
Other ways to read this feed:Feed readerFacebook